Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients with HIV Infection or HIV/Hepatitis C Virus Coinfection

David Nicolás, Anna Esteve, Anna Cuadros, Colin N.J. Campbell, Cristina Tural, Daniel Podzamczer, Javier Murillas, Francesc Homar, Ferrán Segura, Lluis Force, Josep Vilaró, Àngels Masabeu, Isabel Garcia, Jordi Mercadal, Alexandra Montoliu, Elena Ferrer, Melcior Riera, Carmen Cifuentes, Juan Ambrosioni, Gemma NavarroChristian Manzardo, Bonaventura Clotet, Josep M. Gatell, Jordi Casabona, José M. Miró

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)


© 2016 The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Background. It has been suggested that routine CD4 cell count monitoring in human immunodeficiency virus (HIV)-monoinfected patients with suppressed viral loads and CD4 cell counts >300 cell/μL could be reduced to annual. HIV/hepatitis C virus (HCV) coinfection is frequent, but evidence supporting similar reductions in CD4 cell count monitoring is lacking for this population. We determined whether CD4 cell count monitoring could be reduced in monoinfected and coinfected patients by estimating the probability of maintaining CD4 cell counts ≥200 cells/μL during continuous HIV suppression. Methods. The PISCIS Cohort study included data from 14 539 patients aged ≥16 years from 10 hospitals in Catalonia and 2 in the Balearic Islands (Spain) since January 1998. All patients who had at least one period of 6 months of continuous HIV suppression were included in this analysis. Cumulative probabilities with 95% confidence intervals were calculated using the Kaplan-Meier estimator stratified by the initial CD4 cell count at the period of continuous suppression initiation. Results. A total of 8695 patients were included. CD4 cell counts fell to <200 cells/μL in 7.4% patients, and the proportion was lower in patients with an initial count >350 cells/μL (1.8%) and higher in those with an initial count of 200-249 cells/μL (23.1%). CD4 cell counts fell to <200 cells/μL in 5.7% of monoinfected and 11.1% of coinfected patients. Of monoinfected patients with an initial CD4 cell count of 300-349 cells/μL, 95.6% maintained counts ≥200 cells/μL. In the coinfected group with the same initial count, this rate was lower, but 97.6% of coinfected patients with initial counts >350 cells/μL maintained counts ≥200 cells/μL. Conclusions. From our data, it can be inferred that CD4 cell count monitoring can be safely performed annually in HIV-monoinfected patients with CD4 cell counts >300 cells/μL and HIV/HCV-coinfected patients with counts >350 cells/μL.
Original languageEnglish
Pages (from-to)1578-1585
JournalClinical Infectious Diseases
Issue number12
Publication statusPublished - 15 Jun 2016


  • CD4 cell count
  • HIV-1
  • HIV-1 suppression
  • HIV-1/HCV coinfection


Dive into the research topics of 'Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients with HIV Infection or HIV/Hepatitis C Virus Coinfection'. Together they form a unique fingerprint.

Cite this